RENB vs. GLSI, IXHL, CAPR, CRVO, IMAB, PRQR, SCPH, ACET, RZLT, and ATOS
Should you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include Greenwich LifeSciences (GLSI), Incannex Healthcare (IXHL), Capricor Therapeutics (CAPR), CervoMed (CRVO), I-Mab (IMAB), ProQR Therapeutics (PRQR), scPharmaceuticals (SCPH), Adicet Bio (ACET), Rezolute (RZLT), and Atossa Therapeutics (ATOS). These companies are all part of the "pharmaceutical preparations" industry.
Greenwich LifeSciences (NASDAQ:GLSI) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.
Greenwich LifeSciences' return on equity of -81.25% beat Renovaro's return on equity.
Greenwich LifeSciences currently has a consensus price target of $36.00, indicating a potential upside of 173.14%. Given Renovaro's higher possible upside, equities analysts plainly believe Greenwich LifeSciences is more favorable than Renovaro.
Greenwich LifeSciences has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500.
In the previous week, Greenwich LifeSciences had 1 more articles in the media than Renovaro. MarketBeat recorded 2 mentions for Greenwich LifeSciences and 1 mentions for Renovaro. Renovaro's average media sentiment score of 0.03 beat Greenwich LifeSciences' score of 0.00 indicating that Greenwich LifeSciences is being referred to more favorably in the media.
Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks.
4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 71.4% of Renovaro shares are owned by institutional investors. 52.9% of Greenwich LifeSciences shares are owned by company insiders. Comparatively, 21.7% of Renovaro shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Greenwich LifeSciences received 5 more outperform votes than Renovaro when rated by MarketBeat users.
Summary
Greenwich LifeSciences beats Renovaro on 8 of the 12 factors compared between the two stocks.
Get Renovaro News Delivered to You Automatically
Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Renovaro Competitors List
Related Companies and Tools
